Search research articles
Contact Us
Filters
Showing results (81-90 of 145) with videos related to
Page
of 15
Sort By:
Frontiers in Oncology
|
October 17, 2022
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
Laura Ballotta, Omar Simonetti, Pierlanfranco D'Agaro, et al.
Blood
|
January 17, 2012
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters
Gian Matteo Rigolin, Francesca Cibien, Sara Martinelli, et al.
Haematologica
|
April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
Blood
|
September 27, 2013
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism
Antonella Zucchetto, Chiara Caldana, Dania Benedetti, et al.
Haematologica
|
October 30, 2020
<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
Federico Pozzo, Tamara Bittolo, Erika Tissino, et al.
Leukemia Research
|
February 12, 2022
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
Annals of Hematology
|
February 22, 2012
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo, et al.
Haematologica
|
November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
Francesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Journal of Clinical Medicine
|
February 13, 2025
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers
Giulia Battaglia, Davide Lazzarotto, Ilaria Tanasi, et al.
The New England Journal of Medicine
|
July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 145) with videos related to
Sort By:
Page
of 15
Frontiers in Oncology
|
October 17, 2022
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
Laura Ballotta, Omar Simonetti, Pierlanfranco D'Agaro, et al.
Blood
|
January 17, 2012
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters
Gian Matteo Rigolin, Francesca Cibien, Sara Martinelli, et al.
Haematologica
|
April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
Blood
|
September 27, 2013
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism
Antonella Zucchetto, Chiara Caldana, Dania Benedetti, et al.
Haematologica
|
October 30, 2020
<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
Federico Pozzo, Tamara Bittolo, Erika Tissino, et al.
Leukemia Research
|
February 12, 2022
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, et al.
Annals of Hematology
|
February 22, 2012
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo, et al.
Haematologica
|
November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
Francesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
Journal of Clinical Medicine
|
February 13, 2025
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers
Giulia Battaglia, Davide Lazzarotto, Ilaria Tanasi, et al.
The New England Journal of Medicine
|
July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Page
of 15